Recombinant Human Plasma Gelsolin
Sars-CoV2
BioAegis Therapeutics Inc.Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
32 Active assets in the Sars-CoV2 cohort.
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →